Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice

Andrea Leiva*, Susana Contreras-Duarte, Ludwig Amigo, Esteban Sepúlveda, Mauricio Boric, Verónica Quiñones, Dolores Busso, Attilio Rigotti

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic±diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61h/h) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population.

Original languageEnglish
Article numbere0184280
JournalPLoS ONE
Issue number9
StatePublished - Sep 2017

Bibliographical note

Funding Information:
Funding:ThisworkwasfundedbytheChilean NationalResearchandTechnologyCommission (Comisio ´n Nacional de Investigacio ´n Cientı ´fica y Tecnolo ´ gica,CONICYT),FondoNacionalde Desarrollo Cientı ´ fico y Tecnolo ´ gico grant #1070634 (A.Rigotti),#1150399(A.Rigotti),#1150344(A. Leiva)andCONICYTPh.D.fellowships(A.Leiva,E.

Publisher Copyright:
© 2017 Leiva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


  • Animals
  • Atherosclerosis
  • Endothelium, Vascular
  • Hypercholesterolemia
  • LDL-Receptor Related Proteins
  • Male
  • Mice
  • Mice, Knockout
  • Myocardial Ischemia
  • Plant Extracts
  • Plant Gums
  • Scavenger Receptors, Class B


Dive into the research topics of 'Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice'. Together they form a unique fingerprint.

Cite this